PDF(Pubmed)
Abstract：
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment standards and significantly enhanced patient prognoses. However, the utilization of these groundbreaking therapies has led to the observation and reporting of various types of adverse events, commonly known as immune-related adverse events (irAEs). In the following article, we present four patients who encountered uncommon toxicities induced by ICIs. The first patient was a 59-year-old female diagnosed with stage 4 lung adenocarcinoma. She received immunotherapy (pembrolizumab) together with chemotherapy and subsequently developed autonomic neuropathy (AN). The next two patients also received chemo-immunotherapy (pembrolizumab) and were both 63-year-old males with stage 4 lung adenocarcinoma. One of the two experienced palmoplantar keratoderma, while the other presented with Reiter\'s syndrome (urethritis, conjunctivitis and arthritis). The 4th patient, an 80-year-old male with stage 4 squamous cell carcinoma of the lung, received chemo-immunotherapy (pembrolizumab) and developed myasthenia gravis.
摘要：
免疫检查点抑制剂（ICI）的引入彻底改变了癌症治疗标准，并显着提高了患者的预后。然而,这些开创性疗法的使用导致了各种类型的不良事件的观察和报告，通常称为免疫相关不良事件（irAEs）。在下面的文章中，我们介绍了4例因ICIs引起的罕见毒性反应的患者.第一位患者是诊断为4期肺腺癌的59岁女性。她接受了免疫治疗（pembrolizumab）和化疗，随后发展为自主神经病变（AN）。接下来的两名患者也接受了化学免疫疗法（pembrolizumab），并且都是63岁的男性，患有4期肺腺癌。其中一个经历了掌plant角化病，而另一个则患有瑞特综合征(尿道炎，结膜炎和关节炎)。第四个病人,一名80岁的男性患有4期肺鳞状细胞癌，接受了化学免疫治疗(pembrolizumab)并发展为重症肌无力.
